Christina Wu
0000-0001-5922-5392
Publication & Citation Trends
Most Cited Works
Publications
342 total
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Cited by 228
OpenAlex
Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. OA
Cited by 47
Semantic Scholar
PD04-10 PRE-CLINICAL STUDIES TO ADVANCE ZILOVERTAMAB-BASED ANTI-ROR1 DUAL SPECIFICITY CAR T-CELL THERAPY FOR METASTATIC PROSTATE CANCER.
Cited by 0
Semantic Scholar
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer PDF
Cited by 120
OpenAlex
Basal-Luminal Hybrid Cells Emerge as a New Dormant, Androgen Pathway Directed Therapy-Resistant Population in Patient-Derived Prostate Cancer Organoids
Cited by 0
Semantic Scholar
A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand OA
Cited by 37
Semantic Scholar
MP33-03 DORMANT CASTRATION-RESISTANT PROSTATE CANCER ORGANOIDS WITH HYBRID BASAL-LUMINAL CELLS AND LOSS OF SARS-COV-2 HOST FACTORS EMERGED UNDER ANDROGEN DEPRIVATION
Cited by 0
Semantic Scholar
A combined Globo H-OCT4-T7 immunotherapy restrains colorectal tumor growth OA
Cited by 1
Semantic Scholar
Research Topics
Colorectal Cancer Treatments and Studies
(134)
Genetic factors in colorectal cancer
(54)
Pancreatic and Hepatic Oncology Research
(50)
Gastric Cancer Management and Outcomes
(47)
Cancer Genomics and Diagnostics
(42)
Frequent Co-Authors
Affiliations
Western University
Emory Healthcare
Hudson Institute
The University of Texas MD Anderson Cancer Center
Harvard University